Pharma Thriller: ImClone’s Secret Suitor Remains Cloaked In Mystery
Eli Lilly is rumored to be the admirer, offering $70 per share to outbid rival Bristol-Myers Squibb.
Eli Lilly is rumored to be the admirer, offering $70 per share to outbid rival Bristol-Myers Squibb.